Drugs / Ga-68 PSMA ligand
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03207139 | Jun 2017 → Jun 2019 | prostate cancer | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04951817 | Mar 2022 → Aug 2025 overdue | metastatic prostate carcinoma | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| — | NCT03977610 | Jun 2019 → Jul 2021 | metastatic prostate carcinoma | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga-68 PSMA ligand | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03207139 ↗ |
| Known as | Ga68-PSMA-11 (Gallium-68 labeled HBED-CC PSMA) | “Ga68-PSMA-11 (Gallium-68 labeled HBED-CC PSMA)” NCT03977610 ↗ |
| Modality | Diagnostic / imaging agent | “The primary endpoint is diagnostic sensitivity of the Ga-68 PSMA ligand in prostate cancer.” NCT03207139 ↗ |
| Route | Intravenous | “single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand” NCT03207139 ↗ |